DOP2006000221A - Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepción oral - Google Patents
Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepción oralInfo
- Publication number
- DOP2006000221A DOP2006000221A DO2006000221A DO2006000221A DOP2006000221A DO P2006000221 A DOP2006000221 A DO P2006000221A DO 2006000221 A DO2006000221 A DO 2006000221A DO 2006000221 A DO2006000221 A DO 2006000221A DO P2006000221 A DOP2006000221 A DO P2006000221A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- combination
- estradiol
- units
- dienogest
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Se efectua el use de valerato de estradiol en combinación con 170-cianometil-17-B-hidroxiestra-4,9-dien-3-ona (dienogest) para producir un preparado combinado polifasico para la terapia oral de hemorragia uterina disfuncional en combinacido con una anticoncepcibo oral. La combinación de valerato de estradiol con dienogest comprende en este caso una primera fase de 2 unidades de dosis diarias del valerato de estradiol de 3 mg o estradiol inferior a 3 mg, una segunda fase de 2 grupos de unidades de dosis diarias, en donde el primer grupo contiene 5 unidades de dosis diarias de una combinación de 2 mg de valerato de estradiol o estradiol inferior a 2 mg y 2 mg de dienogest y el segundo grupo contiene 17 unidades de dosis diarias de una combinación de 2 mg de valerato de estradiol o estradiol inferior a 2 mg y 3 mg de dienogest, una tercera fase de 2 unidades de dosis diarias con 1 mg de valerato de estradiol o estradiol inferior a 1 mg y otra fase de 2 unidades de dosis diarias de placebo farmaceuticamente inocuo. Todas las unidades de dosis diarias de la combinación polifasica y del placebo farmaceuticamente inocuo corresponden a 28 dias. La duración de la aplicación comprende al menos un ciclo de ingesta y depende del deseo individual de la mujer de la anticoncepción.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05022324A EP1787649B1 (de) | 2005-10-13 | 2005-10-13 | Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2006000221A true DOP2006000221A (es) | 2007-08-31 |
Family
ID=35811580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2006000221A DOP2006000221A (es) | 2005-10-13 | 2006-10-13 | Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepción oral |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1787649B1 (es) |
JP (2) | JP5735200B2 (es) |
KR (2) | KR101218872B1 (es) |
CN (1) | CN101312733A (es) |
AR (1) | AR056694A1 (es) |
AT (2) | ATE424828T1 (es) |
CA (1) | CA2623024C (es) |
CL (1) | CL2011000283A1 (es) |
CY (2) | CY1110321T1 (es) |
DE (2) | DE502005006837D1 (es) |
DK (2) | DK1787649T3 (es) |
DO (1) | DOP2006000221A (es) |
ES (2) | ES2322479T3 (es) |
HR (1) | HRP20090256T1 (es) |
ME (1) | ME01056B (es) |
PE (2) | PE20070555A1 (es) |
PL (2) | PL1787649T3 (es) |
PT (2) | PT1787649E (es) |
SI (2) | SI1787649T1 (es) |
TW (2) | TWI328453B (es) |
UY (1) | UY29861A1 (es) |
WO (1) | WO2007042296A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
EP1787649B1 (de) * | 2005-10-13 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption |
US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
WO1998004265A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
EP1462106A1 (en) * | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
EP1787649B1 (de) * | 2005-10-13 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption |
-
2005
- 2005-10-13 EP EP05022324A patent/EP1787649B1/de not_active Revoked
- 2005-10-13 AT AT05022324T patent/ATE424828T1/de active
- 2005-10-13 ES ES05022324T patent/ES2322479T3/es active Active
- 2005-10-13 ME MEP-2009-171A patent/ME01056B/me unknown
- 2005-10-13 SI SI200530672T patent/SI1787649T1/sl unknown
- 2005-10-13 DE DE502005006837T patent/DE502005006837D1/de active Active
- 2005-10-13 PL PL05022324T patent/PL1787649T3/pl unknown
- 2005-10-13 DK DK05022324T patent/DK1787649T3/da active
- 2005-10-13 PT PT05022324T patent/PT1787649E/pt unknown
-
2006
- 2006-10-12 PE PE2006001241A patent/PE20070555A1/es not_active Application Discontinuation
- 2006-10-12 EP EP06806225A patent/EP1933843B1/de active Active
- 2006-10-12 KR KR1020107014574A patent/KR101218872B1/ko active IP Right Grant
- 2006-10-12 DK DK06806225.6T patent/DK1933843T3/da active
- 2006-10-12 PT PT06806225T patent/PT1933843E/pt unknown
- 2006-10-12 PL PL06806225T patent/PL1933843T3/pl unknown
- 2006-10-12 CN CNA2006800381810A patent/CN101312733A/zh active Pending
- 2006-10-12 AT AT06806225T patent/ATE497387T1/de active
- 2006-10-12 CA CA2623024A patent/CA2623024C/en active Active
- 2006-10-12 PE PE2009001256A patent/PE20100090A1/es not_active Application Discontinuation
- 2006-10-12 WO PCT/EP2006/009867 patent/WO2007042296A1/de active Application Filing
- 2006-10-12 DE DE502006008853T patent/DE502006008853D1/de active Active
- 2006-10-12 SI SI200630991T patent/SI1933843T1/sl unknown
- 2006-10-12 JP JP2008534936A patent/JP5735200B2/ja active Active
- 2006-10-12 KR KR1020087011203A patent/KR20080065651A/ko not_active Application Discontinuation
- 2006-10-12 TW TW095137564A patent/TWI328453B/zh active
- 2006-10-12 ES ES06806225T patent/ES2360302T3/es active Active
- 2006-10-13 UY UY29861A patent/UY29861A1/es not_active Application Discontinuation
- 2006-10-13 AR ARP060104489A patent/AR056694A1/es not_active Application Discontinuation
- 2006-10-13 DO DO2006000221A patent/DOP2006000221A/es unknown
-
2007
- 2007-01-09 TW TW096100872A patent/TW200829255A/zh unknown
-
2009
- 2009-05-05 HR HR20090256T patent/HRP20090256T1/xx unknown
- 2009-06-11 CY CY20091100621T patent/CY1110321T1/el unknown
-
2011
- 2011-02-10 CL CL2011000283A patent/CL2011000283A1/es unknown
- 2011-05-02 CY CY20111100422T patent/CY1111406T1/el unknown
-
2012
- 2012-11-19 JP JP2012253067A patent/JP2013047269A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160297A2 (es) | Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
ES2399105T3 (es) | Anticonceptivo estrogénico cuadrifásico graduado de manera continua | |
AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
JP2010180236A5 (es) | ||
PE20060485A1 (es) | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
JP2007535519A5 (es) | ||
HRP20070188A2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
AR048722A1 (es) | Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos | |
AR084229A2 (es) | Preparado polifasico para la contracepcion a base de un estrogeno natural | |
AR051931A1 (es) | Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes | |
JP2010539153A5 (es) | ||
AR061959A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
DOP2006000221A (es) | Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepción oral | |
AR065816A1 (es) | Regimen anticonceptivo oral | |
CR8010A (es) | Regimenes de contraceptivos transdermicos extendidos | |
AR053545A1 (es) | Preparacion farmaceutica para la anticoncepcion oral | |
EA200701389A1 (ru) | Твёрдая пероральная лекарственная форма для контрацепции | |
AR049195A1 (es) | Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento | |
CY1112775T1 (el) | Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος | |
PE20070769A1 (es) | Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional | |
AR062323A1 (es) | Forma farmacologica peroral para la anticoncepcion | |
RS50849B (sr) | Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu | |
TH148141A (th) | การใช้เอสตราไดออลวาเลอเรตหรือเอสตราไดออลร่วมกับไดอีโนเจสต์สำหรับการรักษาโดยให้ทางปากในการตกเลือดในมดลูกแบบที่ทำงานผิดปกติ ร่วมกับยาคุมกำเนิดสำหรับให้ทางปาก | |
UY29378A1 (es) | Preparación farmaceutica para la anticoncepción oral | |
TH98166B (th) | การจัดการการเกิดการตกเลือดอย่างมากในการจัดควบคุมยาคุมกำเนิดชนิดฮอร์โมนแบบมีการขยายเวลา |